Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bintrafusp alfa + cisplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Bintrafusp alfa + cisplatin + pemetrexed is a pharmaceutical combination therapy comprising **bintrafusp alfa**, a first-in-class bifunctional fusion protein targeting both transforming growth factor-beta (TGF-β) and programmed death-ligand 1 (PD-L1); **cisplatin**, a platinum-based chemotherapeutic agent; and **pemetrexed**, an antifolate chemotherapy agent. Bintrafusp alfa works by simultaneously blocking PD-L1-mediated immune evasion and sequestering TGF-β in the tumor microenvironment, which may enhance antitumor immunity and inhibit tumor-promoting effects of TGF-β[1][2][3]. Cisplatin induces DNA cross-linking leading to apoptosis, while pemetrexed inhibits folate-dependent enzymes critical for DNA synthesis. This combination is used mainly in clinical trials for advanced non-small cell lung cancer (NSCLC) and other solid tumors[1][3]. The regimen is administered intravenously.
- Brand names
- None
- Other names
- bintrafusp alfa + cisplatin + pemetrexed
02
Targets
GART (GAR transformylase)TS (Thymidylate synthase)TGFB (GARP–latent transforming growth factor beta 1 complex)CD274 (Programmed cell death protein 1 ligand 1)DNADHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on bintrafusp alfa + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bintrafusp alfa + cisplatin + pemetrexed.